suramin has been researched along with Wilms Tumor in 2 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Wilms Tumor: A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin was found to affect the Wilms' tumor (WT) cell line, W13, by inhibiting in vitro growth (half-maximal inhibitory dose (ID50)=11 microM), insulin like growth factor II (IGF-II) cell binding (ID50 = 10 microM) and IGF-II induced DNA synthesis (ID50 = 8 microM)." | 5.29 | Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. ( Garvin, AJ; Hazen-Martin, DJ; Vincent, TS, 1996) |
| "Suramin was found to affect the Wilms' tumor (WT) cell line, W13, by inhibiting in vitro growth (half-maximal inhibitory dose (ID50)=11 microM), insulin like growth factor II (IGF-II) cell binding (ID50 = 10 microM) and IGF-II induced DNA synthesis (ID50 = 8 microM)." | 1.29 | Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. ( Garvin, AJ; Hazen-Martin, DJ; Vincent, TS, 1996) |
| "Wilms tumor is a common embryonic tumor in childhood." | 1.29 | Autocrine regulation of growth by insulin-like growth factor (IGF)-II mediated by type I IGF-receptor in Wilms tumor cells. ( Qing, RQ; Ruelicke, T; Schmitt, S; Schoenle, EJ; Stallmach, T, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vincent, TS | 1 |
| Hazen-Martin, DJ | 1 |
| Garvin, AJ | 1 |
| Qing, RQ | 1 |
| Schmitt, S | 1 |
| Ruelicke, T | 1 |
| Stallmach, T | 1 |
| Schoenle, EJ | 1 |
2 other studies available for suramin and Wilms Tumor
| Article | Year |
|---|---|
Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Division; Cell Line; DNA, Neoplasm; Dose-Response R | 1996 |
Autocrine regulation of growth by insulin-like growth factor (IGF)-II mediated by type I IGF-receptor in Wilms tumor cells.
Topics: Animals; Binding Sites; Cell Division; Dose-Response Relationship, Drug; Humans; Insulin-Like Growth | 1996 |